Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Sells $27,734.00 in Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Padmanabh P. Bhatt sold 700 shares of the company’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total transaction of $27,734.00. Following the sale, the vice president now owns 10,149 shares of the company’s stock, valued at $402,103.38. The trade was a 6.45 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ:SUPN opened at $39.00 on Thursday. The company has a 50-day simple moving average of $37.04 and a 200 day simple moving average of $34.36. The company has a market capitalization of $2.15 billion, a P/E ratio of 36.45 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a 52-week low of $25.53 and a 52-week high of $39.69.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 EPS for the quarter, topping the consensus estimate of $0.44 by $0.25. The business had revenue of $175.70 million during the quarter, compared to the consensus estimate of $157.35 million. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. Supernus Pharmaceuticals’s revenue was up 14.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.29) EPS. As a group, equities analysts forecast that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current year.

Hedge Funds Weigh In On Supernus Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in SUPN. GAMMA Investing LLC grew its stake in Supernus Pharmaceuticals by 97.1% during the third quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock worth $25,000 after buying an additional 398 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Supernus Pharmaceuticals by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock worth $61,000 after acquiring an additional 352 shares during the period. Newbridge Financial Services Group Inc. acquired a new stake in shares of Supernus Pharmaceuticals during the 4th quarter worth approximately $72,000. KBC Group NV raised its position in Supernus Pharmaceuticals by 53.1% during the fourth quarter. KBC Group NV now owns 2,679 shares of the specialty pharmaceutical company’s stock valued at $97,000 after purchasing an additional 929 shares in the last quarter. Finally, Kennebec Savings Bank bought a new stake in Supernus Pharmaceuticals during the third quarter worth $103,000.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on SUPN. Cowen reissued a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Cantor Fitzgerald assumed coverage on Supernus Pharmaceuticals in a research note on Monday, January 6th. They set an “overweight” rating and a $57.00 target price for the company. Finally, Piper Sandler restated a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.